Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma

Cancer Research

Volumn 72, Issue 16, 2012, Pages 3967-3976

  Suzuki, Yoshiyuki ^c   Mimura, Kousaku ^a,d   Yoshimoto, Yuya ^c   Watanabe, Mitsuaki ^d   Ohkubo, Yu ^c   Izawa, Shinichirou ^d   Murata, Kazutoshi ^c   Fujii, Hideki ^d   Nakano, Takashi ^c   Kono, Koji ^a,b,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; CANCER TESTIS ANTIGEN; CISPLATIN; DOCETAXEL; FLUOROURACIL; HIGH MOBILITY GROUP B1 PROTEIN; TUMOR ANTIGEN;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL DEATH; CHEMORADIOTHERAPY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UPREGULATION;

AGED; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALRETICULIN; CARCINOMA, SQUAMOUS CELL; CELL DEATH; CERCOPITHECUS AETHIOPS; CHEMORADIOTHERAPY; COS CELLS; EPITOPES, T-LYMPHOCYTE; ESOPHAGEAL NEOPLASMS; FEMALE; HMGB1 PROTEIN; HUMANS; MALE; MIDDLE AGED; T-LYMPHOCYTES; TRANSFECTION; UP-REGULATION;

EID: 84865138542     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0851     Document Type: Article

References (31)

1. Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003;21:2697-702. (Pubitemid 46606313)
2. de Manzoni G, Pedrazzani C, Laterza E, Pasini F, Grandinetti A, Bernini M, et al. Induction chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus: impact of increased dosage on long-term results. Ann Thorac Surg 2005;80:1176-83. (Pubitemid 41354085)
3. Cummings B, Keane T, Pintilie M, Warde P, Waldron J, Payne D, et al. Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. Radiother Oncol 2007;85:7-16. (Pubitemid 47562589)
4. Castadot P, Geets X, Lee JA, Gregoire V. Adaptive functional image-guided IMRT in pharyngo-laryngeal squamous cell carcinoma: is the gain in dose distribution worth the effort? Radiother Oncol 2011;101:343-50.
5. Polischouk AG, Grenman R, Granath F, Lewensohn R. Radiosensitivity of human squamous carcinoma cell lines is associated with amount of spontaneous DNA strand breaks. Int J Cancer 2001;96:43-53.
6. Marini P, Schmid A, Jendrossek V, Faltin H, Daniel PT, Budach W, et al. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 2005;5:5.
7. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007;220:47-59. (Pubitemid 350045573)
8. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. NatMed 2007;13:1050-9. (Pubitemid 47517504)
9. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 2008;68:4026-30.
10. Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011;30:61-9.
11. Kepp O, Tesniere A, Zitvogel L, Kroemer G. The immunogenicity of tumor cell death. Curr Opin Oncol 2009;21:71-6.
12. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 2008;20:504-11.
13. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010;29:482-91.
14. Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J, et al. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 2011;71:4821-33.
15. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010;16:3100-4.
16. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13:54-61. (Pubitemid 46067386)
17. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, et al. Autophagy-dependent anticancer immuneresponses induced by chemotherapeutic agents in mice. Science 2011;334:1573-7.
18. Mizukami Y, Kono K, Daigo Y, Takano A, Tsunoda T, Kawaguchi Y, et al. Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci 2008;99:1448-54. (Pubitemid 351761737)
19. Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K, et al. Vaccination with multiple peptides derived from novel cancertestis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 2009;100:1502-9.
20. Harao M, Hirata S, Irie A, Senju S, Nakatsura T, Komori H, et al. HLAA2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumorreactive CTL. Int J Cancer 2008;123:2616-25.
21. Hayama S, Daigo Y, Kato T, Ishikawa N, Yamabuki T, Miyamoto M, et al. Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res 2006;66:10339-48. (Pubitemid 44799753)
22. Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H, et al. Cancertestis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res 2007;67:11601-11.
23. Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 2007;98:1803-08. (Pubitemid 47489730)
24. Togashi A, Katagiri T, Ashida S, Fujioka T, Maruyama O, Wakumoto Y, et al. Hypoxia-inducible protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma and potential target for molecular therapy. Cancer Res 2005;65:4817-26. (Pubitemid 40740820)
25. Shimokawa T, Matsushima S, Tsunoda T, Tahara H, Nakamura Y, Furukawa Y. Identification of TOMM34, which shows elevated expression in the majority of human colon cancers, as a novel drug target. Int J Oncol 2006;29:381-6.
26. Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res 2003;63:4112-8. (Pubitemid 36917935)
27. Daly JM, Weintraub FN, Shou J, Rosato EF, Lucia M. Enteral nutrition during multimodality therapy in upper gastrointestinal cancer patients. Ann Surg;221:327-38.
28. Takagi K, Yamamori H, Furukawa K, Miyazaki M, Tashiro T. Perioperative supplementation of EPA reduces immunosuppression induced by postoperative chemoradiation therapy in patients with esophageal cancer. Nutrition 2001;17:478-9. (Pubitemid 32499544)
29. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002;2:277-88. (Pubitemid 37328781)
30. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
31. Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, Rovere-Querini P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 2007;81:84-91. (Pubitemid 46021256)